Paper Key : IRJ************792
Author: Ms. Supriya Anil Chavhan,Dube Anjali Sanjay,Ms. Gayatri Suresh Kadu,Musale Yogesh Jagnnath ,Musale Yogesh Jagnnath
Date Published: 05 Jan 2023
Abstract
Symptomatic urinary tract infections (UTIs) constitute a major health problem throughout the Western world, Urinary tract infections (UTIs) account for approximately 4 million ambulatory care visits each year. 2-7 Fluoroquinolones, including ciprofloxacin, are suggested as alternatives in communities in which trimethoprimsulfamethoxazole (TMPSMX) resistance associated with uropathies is 10% to 20%. This study systematically reviewed the literature and where appropriate, systematically overviewed studies investigating ciprofloxacin resistance in community- and hospital-acquired bacteria causing UTIs. Complicated urinary tract infections occur in patients with structural abnormalities or comorbidities such as diabetes, old age, pregnancy, or immunocompromised status. Ciprofloxacin is an FDA approved antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections. In this review represents the clinical data of ciprofloxacin causes, symptoms of urinary tract infectionsIntroduction Urinary tract infections (UTIs) are one of the most common infectious diseases worldwide. Approximately >50% of women at least once in their lifetime have suffered from UTI and received antibiotic treatment. Serious UTIs are difficult to treat as it involves a wide array of Gram-positive as well as Gram-negative bacteria. Escherichia coli (E. coli) is the primary causative agent implicated in >80% of UTI cases